Admissions:
None
Delistings:
Craven House Capital (CRV.L) has left AIM
What’s baking in the oven?
Potential** Initial Public Offerings:***
24th July: Scotch Corner Designer Village, a newly formed single asset real estate company (to be re-registered as a public limited company) which is developing a retail outlet and leisure destination, announces it may consider an IPO on the newly launched Aquis Real Asset Market (ARAM) of the Aquis Stock Exchange. Timing and deal details TBC.
Banquet Buffet****
Argo Blockchain 3.05p £21.80m (ARB.L)
The blockchain technology Company focused on large-scale cryptocurrency mining announces that it received a letter from Nasdaq dated 18 July 2025, indicating that Argo has not regained compliance with the minimum bid price requirement pursuant to the cure period provided by Nasdaq Listing Rule 5810(c)(3)(A) by the prescribed deadline of 15 July 2025, and that, as a result, Nasdaq has determined to delist Argo's ADSs (American Depositary Shares) from the Nasdaq Global Select Market. In accordance with the Nasdaq Listing Rules, Argo intends to request a hearing before a Nasdaq Hearings Panel.
Bango 83.50p £64.15m (BGO.L)
The Company that enables content providers to reach more paying customers through global partnerships by opening-up online payments to mobile phone users worldwide made a trading update. The Trading update for the six months to June reported revenue grew by 15% to $8.9m with Annual Recurring Revenue (ARR) up by 21% to $15.6m. The EBITDA is expected to grow by over 60% to more than $6.5m. The net debt increased to $7.3m from $5.1m due to planned working capital investments. There is a new $15m revolving credit loan facility which will enable the acceleration of planned efficiency improvements. New customer momentum is continuing to build, and so far in 2025, seven have been won compared to an average of nine in a twelve month period for the prior two years. The reducing operational expenses and a growing market presence underpin the Board's confidence in meeting full-year market expectations.
Genflow Biosciences 0.85p £3.63m (GENF.L)
The publicly listed longevity Company reported key preclinical activities in two of its lead programs. For GF-1002, in preparation for a submission for European Clinical Trial Authorisation, Genflow is continuing to advance key development activities. To support this process, the Company has initiated Chemistry, Manufacturing, and Controls work in collaboration with its partner, Exothera, to ensure clinical supply production meets Good Manufacturing Practice standards. Genflow has also submitted a first protocol amendment to its ongoing proof-of-concept clinical trial in aged dogs to clarify the administration of its investigational product, GF-1004. The amended protocol now specifies the intravenous dose rate to ensure consistent and controlled delivery, minimising the risk of infusion-related adverse events and reinforcing patient safety.
iomart Group 28.50p £32.14m (IOM.L)
The secure cloud services Company reports its final results for the year ended 31 March 2025. Acquisitions completed in FY24 and the contribution of 6 months of Atech trading delivered overall revenue growth of 13% to £143.5m (2024: £127.0m). Adjusted PBT reduced to £6.5m (2024: £15.0m) reflecting a reduction in adjusted EBIT and the higher interest charges on bank debt post the Atech acquisition. Net debt increased to £101.9m (31 March 2024: £42.3m) following the cash outflow of approximately £57m associated with the acquisition of Atech. Q1 trading was in line with the Board's expectations, recognising that cost reductions are more H2 weighted. The full year effect of net churn in FY25 will impact the run-rate into FY26, but Q1 has achieved positive net order bookings.
Manx Financial Group 24.00p £28.73m (MFX.L)
The holding Company providing a range of diversified financial services to the Isle of Man and UK announces that CAM Wealth Group Ltd, a wholly owned subsidiary, has been granted regulatory permission by the UK FCA to sell and distribute general insurance products within the UK. The new insurance arm, CAM Insurance Solutions, will operate as an integral part of the Group, delivering tailored insurance solutions to support its Group subsidiaries which include one million retail customers and fifteen thousand SMEs before being marketed externally. This is a significant strategic milestone as it expands its financial services.
Nativo Resources 0.28p £0.45m (NTVO.L)
A gold-focused mining Company with interests in Peru announced the adoption of a Digital Asset Treasury Policy to enhance its approach to capital allocation and balance sheet management. As Nativo prepares to restart gold mining operations at the Tesoro Gold Concession, the Board has reviewed its treasury policy. Going forward, subject to working capital requirements, a portion of any free cash flow from mining and processing activities and a proportion of the proceeds of any future fundraises, may be allocated to Bitcoin, which will be held as a long-term treasury reserve asset. The Board believes that exposure to both gold and Bitcoin offers shareholders a unique, diversified hedge against inflation.
Pebble Beach Systems Group 9.00p £11.21m (PEB.L)
The global software business specialising in playout automation and integrated channel solutions for the broadcast and streaming markets makes a trading update for the half-year to June. The revised business strategy and reduced costs has delivered the intended step change in profitability and Pebble now expects FY 25 and FY 26 profitability to be materially ahead of market guidance. Orders grew 32.6% to £6.5m underpinned by strong renewal orders, providing good visibility of future years' revenues. The revenue performance and reduction in overheads means the Group expects to report adjusted EBITDA of £2.0m against H1 2024: £1.4m, with an improved adjusted EBITDA margin of 34% up from 2024: 27%. The net debt is down to £3.3m from £4.8m and with the greater certainty of cashflows the Group re-iterates the expectation of moving to a net cash position during 2026.
SYS Group 20.00p £16.65m (SYS.L)
The cloud, cybersecurity, and AI enablement, delivering end to end solutions at the intersection of cybersecurity and digital transformation for the UK mid-market reports on the FY to March 2025. Revenue decreased 9% to £20m mainly due to a reduction in lower margin services as the gross margin improved to 48.8% from 45.8%. EBITDA reduced to £0.9m from £2.0m in 2024, resulting from investments in overheads to support the strategy to provide full technology solutions. The net Cash Position is £3.6m compared to a Debt position of £(3.4)m after raising £10.6m in June 2024. The Executive Chairman considers that a strong scalable sustainable foundation has been laid for growth through strategic, operational, and financial transformation although near-term conditions remain uncertain-with cautious SME spending and elongated decision cycles.
The Mission Group 25p £22.73m (TMG.L)
The group of digital marketing and communications agencies provides a trading update for the six months to June 2025. The Group expects to report H1 organic revenue of £34.5m compared to June 2024 £35.3m from continuing operations and £42.2m from all operations. This will increase operating profit before adjustments to £2.1m from £1.9m from continuing operations, or £2.6m from all operations. The new Client wins include Google, TikTok International, Accenture and the Federal Reserve Bank of Chicago. There is good progress in Property and Business & Corporate offset by continued challenging trading conditions in Consumer & Lifestyle. Total debt of £16.1m has reduced by £7.9m compared to the equivalent period in 2024. The revenue is H2 weighted and has started with a strong new business pipeline and the Board is confident of delivering profitable growth across all business segments broadly in line with expectations.
Treatt 253.00p £149.15m (TET.L)
The manufacturer and supplier of a diverse and sustainable portfolio of natural extracts and ingredients for the beverage, flavour, and fragrance industries, provides an update on trading for the financial year ending 30 September 2025. Treatt has continued to face trading headwinds since the announcement of the interim results on 13 May 2025 which will affect the performance for the full year. As a result, the Board now expects revenue of between £130m and £135m and profit before tax and exceptionals (PBTE) of between £9m and £11m, lower than previous guidance. This revised outlook has been principally driven by a reduction in second half sales, lower repeat customer volumes, and the weaker US dollar exchange rate.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
